Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Stock Information for Tiziana Life Sciences Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tiziana Life Sciences Ltd

Tiziana Life Sciences Appoints New Chief Executive Officer
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Tiziana Life Sciences Granted FDA Fast Track Designation
Tiziana Receives $3.4 Million in Non-Dilutive Funding
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.